HomeCompareSURYY vs JNJ

SURYY vs JNJ: Dividend Comparison 2026

SURYY yields 0.93% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SURYY wins by $3.58M in total portfolio value
10 years
SURYY
SURYY
● Live price
0.93%
Share price
$13.73
Annual div
$0.13
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.61M
Annual income
$2,991,719.49
Full SURYY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — SURYY vs JNJ

📍 SURYY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSURYYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SURYY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SURYY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SURYY
Annual income on $10K today (after 15% tax)
$79.12/yr
After 10yr DRIP, annual income (after tax)
$2,542,961.57/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, SURYY beats the other by $2,538,975.58/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SURYY + JNJ for your $10,000?

SURYY: 50%JNJ: 50%
100% JNJ50/50100% SURYY
Portfolio after 10yr
$1.82M
Annual income
$1,498,204.45/yr
Blended yield
82.33%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SURYY
No analyst data
Altman Z
1.1
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SURYY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSURYYJNJ
Forward yield0.93%2.13%
Annual dividend / share$0.13$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$3.61M$30.3K
Annual income after 10y$2,991,719.49$4,689.40
Total dividends collected$3.54M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SURYY vs JNJ ($10,000, DRIP)

YearSURYY PortfolioSURYY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,886$186.16$10,592$272.30+$294.00SURYY
2$12,027$378.79$11,289$357.73+$738.00SURYY
3$13,651$782.22$12,123$472.89+$1.5KSURYY
4$16,266$1,659.53$13,141$629.86+$3.1KSURYY
5$21,101$3,696.15$14,408$846.81+$6.7KSURYY
6$31,540$8,962.15$16,021$1,151.60+$15.5KSURYY
7$58,787$25,039.18$18,122$1,588.22+$40.7KSURYY
8$150,136$87,233.77$20,930$2,228.20+$129.2KSURYY
9$577,067$416,421.60$24,792$3,191.91+$552.3KSURYY
10$3,609,181$2,991,719.49$30,274$4,689.40+$3.58MSURYY

SURYY vs JNJ: Complete Analysis 2026

SURYYStock

Sumitomo Realty & Development Co., Ltd. engages in the real estate business in Japan. It operates through five segments: Leasing, Sales, Construction, Brokerage, and Other. The Leasing segment leases and manages office buildings, rental apartments, etc., as well as operates and manages hotels, event halls, retail facilities, land lots, etc. The Sales segment sells condominium units, detached houses, etc. The Construction segment is involved in the construction and remodeling of detached houses, condominiums, etc. The Brokerage segment offers real estate brokerage services, as well as acts as a sales agent of residential properties. The Other segment is involved in the fitness and restaurant businesses. Further, it offers monthly parking lot, house cleaning/housekeeping, interior designing, catering, convenience stores, and insurance and advertisement agency services. It serves corporate and private customers. The company was formerly known as Izumi Real Estate Co., Ltd. and changed its name to Sumitomo Realty & Development Co., Ltd. in 1957. Sumitomo Realty & Development Co., Ltd. was incorporated in 1949 and is headquartered in Tokyo, Japan.

Full SURYY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this SURYY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SURYY vs SCHDSURYY vs JEPISURYY vs OSURYY vs KOSURYY vs MAINSURYY vs ABBVSURYY vs MRKSURYY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.